Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Charous

Otolaryngology Goodyear, AZ Medical Doctor

NPI 1326017336 CMS profile 104840

13555 W McDowell Rd Ste 209, Goodyear, AZ 85395

Open in the dashboard

General payments

$195,801

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$170,844 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Daniel Charous of Goodyear, AZ is reported in the CMS Open Payments database as having received $195,801 across 252 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $170,844 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,901 18
2024 General $20,267 26
2023 General $21,063 24
2022 General $11,138 20
2021 General $15,316 20
2020 General $46,480 53
2019 General $66,634 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Charous
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Daniel Charous were reported at $14,901. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Daniel Charous Otolaryngology median Middle half National median
2019 $66,634 $194 $82–$512 $163
2020 $46,480 $118 $42–$280 $114
2021 $15,316 $167 $63–$444 $132
2022 $11,138 $216 $84–$545 $149
2023 $21,063 $235 $93–$588 $160
2024 $20,267 $280 $111–$699 $164
2025 $14,901 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $125,024 42 payments
  2. Aerin Medical Inc. $34,555 57 payments
  3. Acclarent, Inc $20,041 87 payments
  4. Integra LifeSciences Corporation $13,722 25 payments
  5. Intersect ENT, Inc. $977 13 payments
  6. KARL STORZ Endoscopy-America $665 1 payment
  7. OptiNose US, Inc. $214 11 payments
  8. Preceptis Medical, Inc. $156 1 payment
  9. Stryker Corporation $151 7 payments
  10. Arrinex, Inc. $141 1 payment
  11. Other $156 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $181,550 65 payments
  2. Food and Beverage $7,680 178 payments
  3. Honoraria $3,796 3 payments
  4. Travel and Lodging $2,109 5 payments
  5. Education $665 1 payment
Products named General payments · program years 2019–2025
  1. ACCLARENT NAVWIRE SINUS NAVIGATION GUIDEWIRE $41,352 15 payments
  2. TruDi Navigation System $36,556 50 payments
  3. TruDi Nav Cable $35,738 11 payments
  4. TruDi Nav Suction $35,625 9 payments
  5. VIVAER STYLUS $26,209 23 payments
  6. ACCLARENT AERA $13,722 25 payments
  7. INSPIRA AIR $12,972 24 payments
  8. ACCLARENT Balloon Inflation Device $5,746 6 payments
  9. Acclarent ENT Navigation System $5,674 5 payments
  10. RHINAER STYLUS $4,534 16 payments
  11. Other $20,931 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

229

Median for Otolaryngology: 297

Drug cost

$3,529

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 98 $2,469
Cefdinir Generic 16 $268
Ofloxacin Generic 14 $205
Doxycycline Hyclate Generic 26 $173
Pantoprazole Sodium Generic 33 $143
Mupirocin Generic 20 $143
Methylprednisolone Generic 22 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$442,680

Medicare's payments for the services billed

Medicare patients

328

Average age 75

Services billed

2,731

192 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 56%
Chronic kidney disease 27%
Ischemic heart disease 26%
Diabetes 22%
Depression 21%
Atrial fibrillation 19%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record